Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kesimpta Global Growth in USD by Quarter
Kesimpta Global Growth in USD (% USD) (%)
Novartis Kesimpta Global Growth in USD: 21.0% in Q3 2026, down 25.0 pts from a year earlier. That is the lowest of the 17 quarters on record here.
Latest, Q3 2026
21.0%
Period ended Sep 30, 2026
Change on a year earlier
-25.0 pts
46.0% in Q3 2025
History
17 quarters
Since Q3 2022
Sources
17
Documents cited below
Where the Q3 2026 figure comes from
“|| Kesimpta | 1 484 | 1 222 | 21 | 22”
Source: Novartis Form 6-K (0001114448-26-000014) ↗
Reported in Form 6-K & Form 20-F.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Cite this data
StockData. (2026). Novartis Kesimpta Global Growth in USD (%), quarterly Q3 2022–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta-yoy-usd-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.